HealthTree Logo
search more_vert
close
person Sign In / Create Account
Miami Myeloma MRD Meeting 2024
Miami Myeloma MRD Meeting 2024 image
Minimal Residual Disease (MRD)
event May 09, 2024 / 09:00AM - 01:00PM EDT

Event Description

The Miami Myeloma MRD 2024 Meeting will be hosted by the Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as media partner. Featuring presentations and discussions from leading experts in multiple myeloma.

Schedule & Agenda

person
Live welcome and intro
9:00 AM
person
SESSION I: Current era of MRD testing
9:05 AM

 

 

person
Live discussion – patient perspectives on MRD testing in myeloma
9:55 PM
person
SESSION II: Current and emerging technologies for tracking MRD in myeloma
10:15 AM
person
Live discussion – perspectives on available and new MRD assays in myeloma
11:05 AM
person
Fireside chat with the FDA – what is happening in MRD in myeloma; what is next?
11:25 AM
person
SESSION III: Myeloma MRD testing in the real world?
11:45 AM
person
Live discussion: using MRD in the real world
12:35 AM
person
Live wrap-up and adjourn
12:55 PM

Speakers & Moderators

The panelist C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube